These findings highlight the potential of targeting ELOVL2 as a novel therapeutic strategy to overcome enzalutamide resistance in advanced PCa, offering a promising avenue for improving clinical outcomes in patients with CRPC. This evidence concerns the gene ELOVL2 and posterior cortical atrophy.